Get the app
NSEHealthcare

Hester Biosciences Limited (HESTERBIO)

NSE · Healthcare · Drug Manufacturers - Specialty & Generic

₹2,245.80+1.73%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
₹77 cr
Revenue YoY
-8.2%
Net profit
₹97 cr
Profit YoY
+489.8%
EPS
₹9.09
EPS estimate
₹12.65
Net margin
125.6%

EPS came in at 9.09 against a street estimate of 12.65 — a miss of 28.1%.

Key statistics

Market cap
₹2,108 cr
P/E
13.9
Forward P/E
0.0
P/B
5.13
Book value
₹423.46
EPS (TTM)
₹158.76
52-week high
₹2,683.60
52-week low
₹1,233.94
50-day MA
₹2,373.95
200-day MA
₹1,829.87
Beta
0.41

Shareholding

Promoters
68.78%
Institutions
0.22%

Recent filings & reports

DocumentDate
Annual report FY2026
HESTER BIOSCIENCES LIMITED – FY 2025-26 SUMMARY HEADLINE NUMBERS • Revenue from Operations: INR 2,921.36 Million (FY2025: INR 2,864.66 Million) – gr
2026-06-18
Q4 FY26 earnings call
HESTER BIOSCIENCES LIMITED - FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY26 Revenue Growth: Standalone revenue grew 22%; consolidated revenue grew
2026-05-18
Quarterly results · Q4 FY26
HESTER BIOSCIENCES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • FY 2025-26 Revenue from Operations: INR 2,921.36 million (Standalone), INR 3,325.9
2026-05-15
Q3 FY26 earnings call
HESTER BIOSCIENCES LIMITED – Q3 & 9M FY26 SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue (Standalone): grew 12% year-on-year • Q3 FY26 PAT (Profit After
2026-02-02
Q2 FY26 earnings call
HESTER BIOSCIENCES LIMITED – Q2/H1 FY26 EARNINGS SUMMARY --- HEADLINE NUMBERS • Q2 FY26 Stand-Alone Division Product Sales: INR 64 crores (down 12%
2025-11-14
Quarterly results · Q2 FY26
HESTER BIOSCIENCES LIMITED – FINANCIAL SUMMARY H1 FY2026 (April-September 2025) --- HEADLINE NUMBERS STANDALONE RESULTS (Six Months Ended 30 Septem
2025-11-12
Q1 FY26 earnings call
HESTER BIOSCIENCES LIMITED - Q1 FY 2025-26 SUMMARY HEADLINE NUMBERS • Stand-alone divisional product sales: INR 63 crores (14% decline YoY) • Stand-
2025-08-04
Quarterly results · Q1 FY26
HESTER BIOSCIENCES LIMITED - Q1 FY2025-26 RESULTS SUMMARY HEADLINE NUMBERS STANDALONE RESULTS (Quarter ended 30 June 2025) • Revenue from Operations
2025-08-01

Readable in the app.

Corporate actions

ActionDetailDate
Dividend₹11 / share
ex-date Jul 14, 2026
2026-07-14

Deals & corporate news

AnnouncementDate
Divestment of equity stake in subsidiary Texas Lifesciences
Hester Biosciences Limited has sold its equity stake in Texas Lifesciences Private Limited, a subsidiary company. This is a divestment (selling) of the company's ownership in this subsidiary
2026-03-11

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Hester Biosciences Limited — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.